R&D channel feed – Endpoints News

R&D channel feed

OncoMed’s bad, no good, disastrous month continues as another PhII flops, PhIb trial is shuttered

9 years ago

Roche says its new interim update on hemophilia A drug is positive. But it’s hard to gauge.

9 years ago

New CEOs at Axovant, Destiny and Organovo mark a busy week for the biotech jobs scene

9 years ago

Nine blockbuster drugs to watch are making their debut, aiming at a $16B prize in 2021

9 years ago

The FDA is getting its hands on a ‘human emulation system,’ and Emulate hopes they never let go

9 years ago

OncoMed shares crushed as Celgene-partnered lead drug flops and Bayer takes a pass on options

9 years ago

Roche’s Alecensa trumps Pfizer’s Xalkori in frontline ALK+ lung cancer

9 years ago

Takeda continues global R&D reboot with a new joint venture with PRA

9 years ago

The stellar antibody shop at Regeneron wins a ‘breakthrough’ tag for its next big PhIII drug

9 years ago

Allergan’s Botox misses the bullseye in PhII depression study, but researchers confident they can hit it in a major PhIII

9 years ago

Stepping out as a global player, a restructured Takeda enrolls 20,000-plus in new dengue PhIII in a showdown with Sanofi

9 years ago

Acorda is shifting into survival mode. And it’s going to start by axing more than 100 staffers.

9 years ago

Bristol-Myers joins the IDO rush with its own in-house combo program for Opdivo

9 years ago

NewLink grabs the AACR spotlight with IDO pathway, Keytruda combo -- shares blitzed

9 years ago

Bristol-Myers’ checkpoint star Opdivo fails a PhIII study for glioblastoma

9 years ago

Paratek shares shoot up on a positive PhIII and a slow-mo shot at FDA/EMA OK for its antibiotic

9 years ago

#AACR17 roundup: Bristol-Myers, Merck KGaA and Pfizer in the spotlight, marking progress with checkpoints

9 years ago

#AACR17: Fresh from Merck embrace, fast-growing Incyte pivots into a PhIII IDO1/Opdivo tie-up with Bristol-Myers

9 years ago

Roche, Prothena hustle to PhII with their disease-modifying Parkinson's drug targeting alpha-synuclein

9 years ago

Kite Pharma hits its Q1 deadline on filing a BLA for its pioneering CAR-T, posts improved data

9 years ago

Halozyme slides on an early futility failure for its lead cancer therapy

9 years ago

Merck, Incyte map a Phase III pipeline of their own for a frontline combo of Keytruda and epacadostat

9 years ago

J&J pulls the plug on PhII study for NHL after Darzalex falls short

9 years ago

Fresh turmoil inside Novartis’ revamped CAR-T organization as top exec jumps ship

9 years ago

First page Previous page 302 303 304305306 307 308 Next page Last page